Novacta Biosystems provides biotransformation process design and development capability to companies across the pharmaceutical, fine chemicals and biofuel sectors. Novacta Biosystems stands out from the crowd for the following reasons:
- Highly experienced staff: 85% of founding members were from GSK's natural product and biotransformation teams and/or Zylepsis
- Versatile technology platform
Novacta's capabilities include:
- Enzyme and biocatalyst screening
- Discovery of new enzymes and Biocatalysts from the environment
- Cloning and overexpression
- Enzyme evolution
- Enzyme immobilisation
- Process optimisation and scale-up
- Technology transfer to manufacturing facilities.
Technology Platform
Enzyme collection:
- lipases, esterases
- proteases, amidases
- nitrile hydrolysing enzymes
- glycosidases
- dehydrogenases
- enzymes for nucleoside biosynthesis
Culture collection:
- 1600 microorganisms characterised for biotransformation activity
- 80 proprietary lipase/esterase producers
- 70 amidase producers from enrichment culture
- Cloned enzymes
- 10,000 actinomycetes from Balkan region